Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3413]
News [7779]
Articles [63]
Editorials [9]
Conferences [208]
elearning [49]
Rituximab for b-cell lymphoma and EHA overview
Prof Ulrich Jäger - EHA President and Vienna Medical University, Austria
Rituximab for b-cell lymphoma and EHA overview ( Prof Ulrich Jäger - EHA President and Vienna Medical University, Austria )
19 Jun 2013
Highlights from EHA 2013
Prof Anton Hagenbeek - Universitair Medisch Centrum Utrecht, Heidelberglaan...
Highlights from EHA 2013 ( Prof Anton Hagenbeek - Universitair Medisch Centrum Utrecht, Heidelberglaan, Netherlands )
19 Jun 2013
Second line treatment of multiple myeloma with melphalan prednisone and...
Prof Meletios Dimopoulos - Univeristy of Athens, Greece
Second line treatment of multiple myeloma with melphalan prednisone and lenalidomide ( Prof Meletios Dimopoulos - Univeristy of Athens, Greece )
19 Jun 2013
Challenges facing haematologists treating acute myeloid leukaemia
Dr Dalia Mahmoud - Celgene Corporation, Summit, USA
Challenges facing haematologists treating acute myeloid leukaemia ( Dr Dalia Mahmoud - Celgene Corporation, Summit, USA )
19 Jun 2013
JAK-STAT pathway in malignant and non-malignant cells in myeloproliferative...
Dr Ross Levine - Memorial Sloan-Kettering Cancer Center, New York, USA
JAK-STAT pathway in malignant and non-malignant cells in myeloproliferative neoplasms ( Dr Ross Levine - Memorial Sloan-Kettering Cancer Center, New York, USA )
19 Jun 2013
Cyclophosphamide lenalidomide and dexamethasone in newly diagnosed myeloma
Dr Annamaria Brioli - The Institute of Cancer Research, Sutton, UK
Cyclophosphamide lenalidomide and dexamethasone in newly diagnosed myeloma ( Dr Annamaria Brioli - The Institute of Cancer Research, Sutton, UK )
19 Jun 2013
Addition of obinutuzumab or rituximab to chlorambucil improves outcomes for...
Dr Valentin Goede - University Hospital of Cologne, Germany
Addition of obinutuzumab or rituximab to chlorambucil improves outcomes for chronic lymphocytic leukaemia ( Dr Valentin Goede - University Hospital of Cologne, Germany )
19 Jun 2013
Long-term outcomes with ruxolitinib and best available therapy for the...
Prof Alessandro Vannucchi - University of Florence, Florence, Italy
Long-term outcomes with ruxolitinib and best available therapy for the treatment of myelofibrosis ( Prof Alessandro Vannucchi - University of Florence, Florence, Italy )
19 Jun 2013
Strategies to maintain remission in high risk CD19 lymphoid malignancies
Dr Partow Kebriaei - MD Anderson Cancer Center, Houston, USA
Strategies to maintain remission in high risk CD19 lymphoid malignancies ( Dr Partow Kebriaei - MD Anderson Cancer Center, Houston, USA )
19 Jun 2013
Von Willebrand Factor and ADAMTS13
Dr Evan Sadler - Washington University in St Louis, USA
Von Willebrand Factor and ADAMTS13 ( Dr Evan Sadler - Washington University in St Louis, USA )
19 Jun 2013
Study shows pomalidomide prolongs survival in refractory myeloma patients
Prof Jesus San Miguel - University Hospital of Salamanca, Salamanca, Spain
Study shows pomalidomide prolongs survival in refractory myeloma patients ( Prof Jesus San Miguel - University Hospital of Salamanca, Salamanca, Spain )
18 Jun 2013
Use of Daratumumab, a CD38 monoclonal antibody, in advanced multiple myeloma
Prof Heinrich Lokhorst - Universitair Medisch Centrum Utrecht, Heidelberglaan...
Use of Daratumumab, a CD38 monoclonal antibody, in advanced multiple myeloma ( Prof Heinrich Lokhorst - Universitair Medisch Centrum Utrecht, Heidelberglaan, Netherlands )
18 Jun 2013

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation